P-gp-IN-36 

P-gp-IN-36 is a potent P-glycoprotein (P-gp) inhibitor with an EC₅₀ of approximately 1 μM. P-gp-IN-36 inhibits the efflux function of P-glycoprotein, overcoming P-gp-mediated multidrug resistance in cancer cells. P-gp-IN-36 inhibits STAT3 phosphorylation and reduces total STAT3 expression. P-gp-IN-36 sensitizes P-gp-expressing cancer cells to the cytostatic effects of conventional cytostatic drugs. P-gp-IN-36 can be used for the research of multidrug-resistant cancer^[1].

P-gp-IN-36 (LD) (0.25-64 μM; 30 min) potently inhibits P-gp in P388/MDR cells, with an EC₅₀ of ~1 μM^[1].
P-gp-IN-36 (0.25-64 μM; 30 min) potently inhibits P-gp in CT26 cells^[1].
P-gp-IN-36 (15 h) potently inhibits STAT3 signaling in CT26 cells by reducing both STAT3 phosphorylation and total STAT3 protein expression^[1].
P-gp-IN-36 (0.5-2 μM; 72 h) potently sensitizes P388/MDR cells to the cytostatic effect of Doxorubicin (HY-15142A), reducing the Doxorubicin IC₅₀ by ~86-fold at a concentration of 2 μM^[1].
P-gp-IN-36 (1-4 μM; 48 h) significantly potentiates Doxorubicin-induced apoptosis in P388/MDR cells, reducing live cell populations in a concentration-dependent manner^[1].
P-gp-IN-36 (2 μM; 48 h) potentiates Doxorubicin-induced apoptosis in P388/MDR cells by significantly increasing caspase-3 activity at a concentration of 2 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

754.95

C₄₄H₅₈N₄O₇

CC1=CC=CC(C)=C1OCC(N[C@@H](CC2=CC=CC=C2)C(C[C@@H](CC3=CC=CC=C3)NC([C@H](C(C)C)N4CCCNC4=O)=O)OC(CCC(C(C)C)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Starenko D, et al. Lopinavir Derivative as Potent P-gp Inhibitor Enables Delivery through HPMA Copolymer Conjugates and Overcoming Tumor Chemoresistance to Conventional Cytostatic Drugs. Biomacromolecules. 2026;27(2):1510-1524.  [Content Brief]